Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol.

Parkinson-s disease clinical trials systematic review

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
09 Dec 2023
Historique:
medline: 10 12 2023
pubmed: 10 12 2023
entrez: 9 12 2023
Statut: epublish

Résumé

Parkinson's disease (PD) is a debilitating neurological disorder for which the identification of disease-modifying interventions represents a major unmet need. Diverse trial designs have attempted to mitigate challenges of population heterogeneity, efficacious symptomatic therapy and lack of outcome measures that are objective and sensitive to change in a disease modification setting. It is not clear whether consensus is emerging regarding trial design choices. Here, we report the protocol of a scoping review that will provide a contemporary update on trial design variability for disease-modifying interventions in PD. The Population, Intervention, Comparator, Outcome and Study design (PICOS) framework will be used to structure the review, inform study selection and analysis. The databases MEDLINE, Web of Science, Cochrane and the trial registry ClinicalTrials.gov will be systematically searched to identify published studies and registry entries in English. Two independent reviewers will screen study titles, abstracts and full text for eligibility, with disagreements being resolved through discussion or by a third reviewer where necessary. Data on general study information, eligibility criteria, outcome measures, trial design, retention and statistically significant findings will be extracted into a standardised form. Extracted data will be presented in a descriptive analysis. We will report our findings using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Scoping Review extension. This work will provide an overview of variation and emerging trends in trial design choices for disease-modifying trials of PD. Due to the nature of this study, there are no ethical or safety considerations. We plan to publish our findings in a peer-reviewed journal.

Identifiants

pubmed: 38070893
pii: bmjopen-2023-071641
doi: 10.1136/bmjopen-2023-071641
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e071641

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Marie-Louise Zeissler (ML)

Newcastle University, Newcastle upon Tyne, UK marie-louise.zeissler@plymouth.ac.uk.
Faculty of Health, University of Plymouth, Plymouth, UK.

Timothy Boey (T)

School of Medicine, University of Liverpool, Liverpool, Merseyside, UK.

Danny Chapman (D)

Faculty of Health, University of Plymouth, Plymouth, UK.

Gary Rafaloff (G)

Parkinson's Research Advocate, Westlake, Florida, USA.

Thea Dominey (T)

Faculty of Health, University of Plymouth, Plymouth, UK.

Karen G Raphael (KG)

Oral & Maxillofacial, Radiology and Medicine, New York University, Brooklyn, New York, USA.
Parkinson's Research Advocate, New York, New York, USA.

Susan Buff (S)

Parkinson's Research Advocate, Sunnyvale, California, USA.

Hari Venkatesh Pai (HV)

Queen's Medical Centre, Nottingham, UK.

Emma King (E)

University Hospitals Plymouth NHS Trust, Plymouth, UK.

Paul Sharpe (P)

Faculty of Health, University of Plymouth, Plymouth, UK.

Fintan O'Brien (F)

Faculty of Health, University of Plymouth, Plymouth, UK.

Camille B Carroll (CB)

Newcastle University, Newcastle upon Tyne, UK.
Faculty of Health, University of Plymouth, Plymouth, UK.

Classifications MeSH